Advertisement

Preferential Expansion of CD4+Foxp3+ Regulatory T Cells (Tregs) In Vitro by Tumor Necrosis Factor

  • Chon-Kit Chou
  • Xin ChenEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2111)

Abstract

CD4+Foxp3+ regulatory T cells (Tregs) are a distinct subset of CD4 T cells that play indispensable role in the maintenance of immune homeostasis and prevention of deleterious immune responses to self-antigens. Tumor necrosis factor (TNF) is a key cytokine in the autoimmune inflammatory responses. The effect of TNF on Treg activity was extensively studied in the past decade. We for the first time reported that TNF through TNFR2 preferentially activates and expands Tregs. Our discovery is increasingly supported by the research community; however, some controversial results were reported. The differential results are likely caused by different experimental condition. A standard experiment protocol can help researchers to obtain more consistent results. In this chapter, we detail methods used to examine in vitro effect of exogenous TNF on the proliferative expansion of Tregs in unfractionated mouse CD4+ T cells. The related technic issues are analyzed and discussed.

Key words

CD4+FOXP3+ regulatory T cells (Tregs) Tumor necrosis factor (TNF) TNF receptor 2 (TNFR2) Selective expansion CFSE cell division assay Flow cytometry 

Notes

Acknowledgments

We thank Ms. Tianzhen He, Mr. Shuoyang Liu, and Ms. Jingbin Zheng at Institute of Chinese Medical Sciences, University of Macau, for the help in the preparation of manuscript.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding: This work was supported by University of Macau under Grants MYRG2016-00023-ICMS-QRCM and MYRG2017-00120-ICMS and the Science and Technology Development Fund of Macao S.A.R. (FDCT) under grant 201/2017/A3 and 0056/2019/AFJ. 

References

  1. 1.
    Chen X, Oppenheim JJ (2010) TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun 11:119–134CrossRefGoogle Scholar
  2. 2.
    Vandenabeele P et al (1995) Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5(10):392–399CrossRefGoogle Scholar
  3. 3.
    Chen X et al (2008) Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 180(10):6467–6471CrossRefGoogle Scholar
  4. 4.
    Chen X et al (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 179(1):154–161CrossRefGoogle Scholar
  5. 5.
    Chen X et al (2010) Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 40(4):1099–1106CrossRefGoogle Scholar
  6. 6.
    Chen X et al (2013) TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol 190(3):1076–1084CrossRefGoogle Scholar
  7. 7.
    He T et al (2018) The p38 MAPK inhibitor SB203580 abrogates tumor necrosis factor-induced proliferative expansion of mouse CD4(+)Foxp3(+) regulatory T cells. Front Immunol 9:1556CrossRefGoogle Scholar
  8. 8.
    Hamano R et al (2011) TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 41(7):2010–2020CrossRefGoogle Scholar
  9. 9.
    Chen X et al (2015) IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. FASEB J 29(2):443–454CrossRefGoogle Scholar
  10. 10.
    Zou H et al (2018) Modulation of regulatory T cell activity by TNF receptor type II-targeting pharmacological agents. Front Immunol 9:594CrossRefGoogle Scholar
  11. 11.
    Shaikh F et al (2018) TNF receptor type II as an emerging drug target for the treatment of cancer, autoimmune diseases, and graft-versus-host disease: current perspectives and in silico search for small molecule binders. Front Immunol 9:1382CrossRefGoogle Scholar
  12. 12.
    Nie Y et al (2018) Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Sci Signal 11(511):eaan0790CrossRefGoogle Scholar
  13. 13.
    Chen X, Oppenheim JJ (2017) Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal 10(462):eaal2328CrossRefGoogle Scholar
  14. 14.
    Okubo Y et al (2013) Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep 3:3153CrossRefGoogle Scholar
  15. 15.
    Nguyen DX, Ehrenstein MR (2016) Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med 213(7):1241–1253CrossRefGoogle Scholar
  16. 16.
    Torrey H et al (2017) Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal 10(462):eaaf8608CrossRefGoogle Scholar
  17. 17.
    Grinberg-Bleyer Y et al (2010) Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 120(12):4558–4568CrossRefGoogle Scholar
  18. 18.
    Housley WJ et al (2011) Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 186(12):6779–6787CrossRefGoogle Scholar
  19. 19.
    Chopra M et al (2016) Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med 213(9):1881–1900CrossRefGoogle Scholar
  20. 20.
    Chopra M et al (2013) Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 34(6):1296–1303CrossRefGoogle Scholar
  21. 21.
    Mahmud SA et al (2014) Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol 15(5):473–481CrossRefGoogle Scholar
  22. 22.
    Leclerc M et al (2016) Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood 128(12):1651–1659CrossRefGoogle Scholar
  23. 23.
    Pierini A et al (2016) TNF-alpha priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood 128(6):866–871CrossRefGoogle Scholar
  24. 24.
    Atretkhany KN et al (2018) Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity. Proc Natl Acad Sci U S A 115(51):13051–13056CrossRefGoogle Scholar
  25. 25.
    Zaragoza B et al (2016) Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med 22(1):16–17CrossRefGoogle Scholar
  26. 26.
    Valencia X et al (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108(1):253–261CrossRefGoogle Scholar
  27. 27.
    Itoh M et al (1999) Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162(9):5317–5326PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical SciencesUniversity of MacauMacau SARChina

Personalised recommendations